we should be flying. . ., page-17

Hi Iva,

Difference with Prana is that their target drug markets are much bigger than Alchemia's.

No one has a cure for Alzheimer's, Prana's drug is promising and that would be a blockbuster drug ie 10's of B compared to hundreds of M, single digit B's for Fonda/HyACT.

That is why it is valued more highly even though it is in Phase II. Also many promising drugs are being partnered at this stage so it is running possibly on this as well.

I do like ACL but it is frustrating to be trading in this range when we have so much to look forward to. Fonda revenues have been a little disappointing but I like the deal they did for VAST which I didn't subscribe any value to so the deal/partnership for HA-Irinotecan should be good IMO. Here's hoping!